Literature DB >> 10215734

The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen.

P M Neville1, S Everett, H Langworthy, D Tompkins, N P Mapstone, A T Axon, P Moayyedi.   

Abstract

BACKGROUND: Current guidelines for Helicobacter pylori eradication recommend 7 days of a proton-pump inhibitor, clarithromycin (C), and either metronidazole (M) or amoxycillin (A). A shorter course would be cheaper and could be as effective. AIM: This study was designed to investigate the efficacy of three 5-day regimens based on lansoprazole (L).
METHODS: 168 dyspepsia patients with H. pylori infection were randomized to receive a 5-day course of either LCM, LAC or CALM, and a 13C-urea breath test was performed after 4 weeks to assess eradication.
RESULTS: 160 patients completed the study. Intention-to-treat eradication rates were as follows: LCM 81%, LAC 59%, CALM 88%. LCM and CALM gave significantly better eradication rates than LAC. There was no significant difference in adverse events across the three groups. Logistical regression analysis showed that the specific regimen used and the age of the patient were the only factors influencing eradication outcome.
CONCLUSIONS: Five days of CALM yields acceptable eradication rates, and is cheaper than conventional 7-day proton pump inhibitor-triple therapy. It appears to offer good results in metronidazole-resistant strains of H. pylori. A randomized trial comparing 5-day CALM with conventional 7-day therapy is needed before this regimen can be recommended for routine use.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10215734     DOI: 10.1046/j.1365-2036.1999.00493.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

1.  Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan.

Authors:  Ayako Yanai; Kei Sakamoto; Masao Akanuma; Keiji Ogura; Shin Maeda
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-02-06

2.  Stomach: Quadruple therapy for Helicobacter pylori eradication.

Authors:  Javier P Gisbert
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-07       Impact factor: 46.802

3.  Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication.

Authors:  Abdallah Said Essa; Jennifer Rosenthal Kramer; David Y Graham; Gerhard Treiber
Journal:  Helicobacter       Date:  2009-04       Impact factor: 5.753

Review 4.  New concepts of resistance in the treatment of Helicobacter pylori infections.

Authors:  David Y Graham; Akiko Shiotani
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-04-29

5.  Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond.

Authors:  David Y Graham; Hong Lu; Yoshio Yamaoka
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori.

Authors:  Javier P Gisbert; Xavier Calvet
Journal:  Clin Exp Gastroenterol       Date:  2012-03-13

7.  A Randomized Clinical Trial Comparing Triple Therapy versus Non-bismuth based Quadruple Therapy for the Eradication of Helicobacter Pylori in Kuwait.

Authors:  Ahmad Alfadhli; Mohamed Alboraie; Mostafa Afifi; Abhijit Dangi
Journal:  J Glob Infect Dis       Date:  2022-08-26

8.  Helicobacter pylori Eradication Therapy: Current Availabilities.

Authors:  M Gasparetto; M Pescarin; G Guariso
Journal:  ISRN Gastroenterol       Date:  2012-07-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.